Key points are not available for this paper at this time.
Design
Review
Answers are grounded in this paper and cite their sources.
Advances conceptual basis for intracrine agents targeting RAS and angiogenesis; leaves open clinical translation pending experimental validation.
Intracrines are extracellular signaling peptide factors that can act in the intracellular space after either internalization or retention in the cells that synthesize them. They are structurally diverse and include hormones, growth factors, enzymes, DNA-binding proteins, and other peptide moieties. We have suggested principles of intracrine action and have applied those principles to forms of cellular and tissue differentiation, hormonal responsiveness, and memory. Moreover, recent findings make clear that some currently available pharmaceuticals act via the alteration of intracrine function. Thus, the beginnings of an intracrine pharmacology are at hand and we here review principles applicable to the design of such agents. The intracrine pharmacology of the renin-angiotensin system, angiogenesis, and stem cell development is discussed.
No takes yet. Share an insight, caveat, or question.
Re et al. (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: